Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug;49(8):709-716.
doi: 10.1111/cup.14245. Epub 2022 May 24.

PRAME immunohistochemistry of spitzoid neoplasms

Stephen S Koh  1 , Sean K Lau  1 , Jason V Scapa  1 , David S Cassarino  2
Affiliations

PRAME immunohistochemistry of spitzoid neoplasms

Stephen S Koh et al. J Cutan Pathol. 2022 Aug.

Abstract

Background: Spitzoid melanocytic neoplasms are well known to be diagnostically challenging. Immunohistochemistry (IHC) and molecular approaches have been used as ancillary diagnostic tests. Herein, we investigate the use of PRAME IHC for the assessment of spitzoid melanocytic neoplasms.

Methods: Ten Spitz nevi, 14 atypical Spitz tumors, and 11 spitzoid melanomas were retrieved, and PRAME IHC was scored on a scale of 1-4 (in % quartiles). Intensity of staining was categorized as weak or strong. Cases with no staining received a score of 0. Positive lymph nodes from three spitzoid melanomas were also analyzed.

Results: Spitz nevi, atypical Spitz tumors, and spitzoid melanomas had mean PRAME IHC scores of 1.20, 0.93, and 3.36, respectively. The percentage of cases with a score 3 or higher for each category of spitzoid neoplasms are as follows: Spitz nevus (20%), atypical Spitz tumor (0%), and spitzoid melanoma (82%). Among the spitzoid melanomas, three cases had positive sentinel lymph nodes, which showed PRAME score of 2, 4, and 4 in the metastatic deposits.

Conclusions: Previous reports revealed PRAME IHC as useful tool to distinguish benign from malignant melanocytic lesions. The results presented here are concordant with the prior studies, but expand the application of this marker to Spitz nevi/tumors and spitzoid melanomas. The present findings suggest the potential diagnostic utility of PRAME IHC in the assessment of spitzoid melanocytic lesions, particularly in distinguishing spitzoid melanomas from Spitz nevi and atypical Spitz tumors.

Keywords: PRAME; immunohistochemistry; melanocytic; melanoma; nevi; spitz; spitzoid.

PubMed Disclaimer

References

REFERENCES

    1. Ackerman AB. Discordance among expert pathologists in diagnosis of melanocytic neoplasms. Hum Pathol. 1996;27(11):1115-1116. doi:10.1016/s0046-8177(96)90301-9
    1. Farmer ER, Gonin R, Hanna MP. Discordance in the histopathologic diagnosis of melanoma and melanocytic nevi between expert pathologists. Hum Pathol. 1996;27(6):528-531. doi:10.1016/s0046-8177(96)90157-4
    1. Troxel DB. Medicolegal aspects of error in pathology. Arch Pathol Lab Med. 2006;130(5):617-619. doi:10.5858/2006-130-617-MAOEIP
    1. Prieto VG. Cutaneous melanocytic lesions: do not miss the invisible gorilla. Adv Anat Pathol. 2012;19(4):263-269. doi:10.1097/PAP.0b013e31825c6be2
    1. Garola R, Singh V. Utility of p16-Ki-67-HMB45 score in sorting benign from malignant Spitz tumors. Pathol Res Pract. 2019;215(10):152550. doi:10.1016/j.prp.2019.152550

LinkOut - more resources